Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.

@article{UlrichPur2001MulticenterPI,
  title={Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.},
  author={Herbert Ulrich-Pur and Gabriela Verena Kornek and Wolfgang Fiebiger and Claudia Gedlicka and Markus Raderer and Alfred Lenauer and Dieter Depisch and Fritz Lang and Johann Pidlich and Werner Scheithauer},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2001},
  volume={12 9},
  pages={1269-72}
}
BACKGROUND A multicenter phase II trial was initiated to investigate the efficacy and tolerance of a dose-fractionated administration schedule of irinotecan in patients with advanced colorectal cancer pre-treated with fluoropyrimidine/ oxaliplatin-based first-line combination chemotherapy. PATIENTS AND METHODS 38 patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding systemic chemotherapy with oxaliplatin in combination with 5… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Similar Papers

Loading similar papers…